Age, higher dose, longer treatment predict symptoms in MTX poisoning
13 May 2021
Clear communication with patients is necessary to prevent therapeutic errors when prescribing methotrexate (MTX) for the first time, according to a study. Older age, higher total dose, and longer treatment duration are predictive of the presence of clinical manifestations.
Management of MDROs in the ICU and the role of newer antimicrobial agents
30 Mar 2021;
Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.